Literature DB >> 6965909

Increased toxicity of diphtheria toxin for human lymphoblastoid cells following covalent linkage to anti-(human lymphocyte) globulin or its F(ab')2 fragment.

W C Ross, P E Thorpe, A J Cumber, D C Edwards, C A Hinson, A J Davies.   

Abstract

Anti-(human lymphocyte) globulin was reacted with a mixed anhydride derivative of chlorambucil to give a product which was in turn reacted with diphtheria toxin. The resulting conjugate was partially purified and was found to possess an ability similar to that of the native antibody to bind to the human lymphoblastoid cell lines, CLA4 and Daudi. Daudi cells, as had been observed previously with CLA4 cells, lacked the high sensitivity to diphtheria toxin normally characteristic of cells of human origin. Thus treatment with free toxin at a concentration of 1 microgram/ml was without effect upon their ability to incorporate [3H]leucine. By contrast, Daudi cells were highly sensitive to toxin conjugated to anti-(human lymphocyte) globulin or to its F(ab')2 fragment. Exposure for 24 h to a solution of conjugate containing toxin at a concentration of 0.5 ng/ml caused a reduction of 50% in the leucine uptake by Daudi cells. The toxicity of the conjugate could be blocked by diphtheria antitoxin or by pretreatment of the cells with non-conjugated antibody. Toxin linked to normal horse IgG or to its F(ab')2 fragment was without cytotoxic effect upon Daudi cells. Furthermore both the conjugate with anti-(human lymphocyte) globulin and that with normal IgG were approximately 100-fold less able than non-conjugated toxin to inhibit protein synthesis by a human fibroblast cell line to which the antibody showed no appreciable binding. Thus the conjugates are relatively ineffective against cells which lack an antigen to which the antibody moiety can bind. In contrast with the greatly increased toxicity of diphtheria toxin for human lymphoblastoid cells following its linkage to anti-(human lymphocyte) globulin, a conjugate of toxin linked to anti-(mouse lymphocyte) globulin was ineffective against murine spleen cells in vitro.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6965909     DOI: 10.1111/j.1432-1033.1980.tb04438.x

Source DB:  PubMed          Journal:  Eur J Biochem        ISSN: 0014-2956


  9 in total

1.  Selective killing of normal or neoplastic B cells by antibodies coupled to the A chain of ricin.

Authors:  K A Krolick; C Villemez; P Isakson; J W Uhr; E S Vitetta
Journal:  Proc Natl Acad Sci U S A       Date:  1980-09       Impact factor: 11.205

2.  The effect of abrin, anti-lymphocyte globulin and their conjugates on the immune response of mice to sheep red blood cells.

Authors:  D C Edwards; A Smith; W C Ross; A J Cumber; P E Thorpe; A J Davies
Journal:  Experientia       Date:  1981-03-15

3.  Monoclonal antibody and an antibody-toxin conjugate to a cell surface proteoglycan of melanoma cells suppress in vivo tumor growth.

Authors:  T F Bumol; Q C Wang; R A Reisfeld; N O Kaplan
Journal:  Proc Natl Acad Sci U S A       Date:  1983-01       Impact factor: 11.205

4.  Synthesis of a covalent epirubicin-(C(3)-amide)-anti-HER2/neu immunochemotherapeutic utilizing a UV-photoactivated anthracycline intermediate.

Authors:  Cody P Coyne; Toni Jones; Ryan Bear
Journal:  Cancer Biother Radiopharm       Date:  2011-12-22       Impact factor: 3.099

5.  Abrogation of the non-specific toxicity of abrin conjugated to anti-lymphocyte globulin.

Authors:  P E Thorpe; A J Cumber; N Williams; D C Edwards; W C Ross; A J Davies
Journal:  Clin Exp Immunol       Date:  1981-01       Impact factor: 4.330

6.  Ricin A immunotoxins of IgG and Fab of anti-CALLA monoclonal antibody: effect of water soluble long-chain SPDP on conjugate yield, immunoselectivity and cytotoxicity.

Authors:  B H Woo; J T Lee; K C Lee
Journal:  Arch Pharm Res       Date:  1994-12       Impact factor: 4.946

7.  Approval of tagraxofusp-erzs for blastic plasmacytoid dendritic cell neoplasm.

Authors:  Naveen Pemmaraju; Marina Konopleva
Journal:  Blood Adv       Date:  2020-08-25

Review 8.  Natural and Designed Toxins for Precise Therapy: Modern Approaches in Experimental Oncology.

Authors:  Olga Shilova; Elena Shramova; Galina Proshkina; Sergey Deyev
Journal:  Int J Mol Sci       Date:  2021-05-07       Impact factor: 5.923

9.  In vivo therapy of a murine B cell tumor (BCL1) using antibody-ricin A chain immunotoxins.

Authors:  K A Krolick; J W Uhr; S Slavin; E S Vitetta
Journal:  J Exp Med       Date:  1982-06-01       Impact factor: 14.307

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.